9 completed, 3 terminated, 2 unknown, 1 active not recruiting. 9 Phase 1, 7 Phase 2, 2 Not applicable.
Follow Unresectable Malignant Neoplasm: new trials by email Literature Review of Unresectable Malignant Neoplasm trials Research Report on Unresectable Malignant Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Proton and Proton-Photon Hybrid Partial Stereotactic Ablative Boost Radiotherapy (P-SABR) for Unresectable Large Tumors Proton P-SABR, Proton-Photon Hybrid P-SABR - Unresectable Malignant Neoplasm, Bulky Tumor | Not yet recruiting | Peking University First Hospital | 60 | 2026-10-01 | 2026-09-14 | |
| Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE) Data collection - Malignant Pleural Mesothelioma, Unresectable Malignant Neoplasm | Completed | Groupe Francais De Pneumo-Cancerologie | 204 | 2022-05-03 | 2025-10-06 | |
| Colorectal Metastasis and Liver Transplantation With Organs From Deceased Donors Liver Transplant, Chemotherapy - Colorectal Liver Metastases, Colorectal Adenocarcinoma | Not applicable | Unknown | Azienda Ospedaliera di Padova | 18 | 2020-10-01 | 2021-05-04 |
| A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer Radiotherapy, Nimotuzumab, S-1 - Esophageal Cancer, Chemoradiotherapy | Phase 2 | Completed | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 55 | 2019-11-14 | 2024-05-16 |
| Chemoradiotherapy in Unresectable Esophageal Cancer Radiotherapy, Albumin-Bound Paclitaxel, Cisplatin - Esophageal Cancer, Chemoradiotherapy | Phase 1 / Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 105 | 2019-10-01 | 2024-12-13 |
| ImmunoPET With an Anti-CD8 Imaging Agent Anti-CD8 PET imaging agent - Metastatic Cancer, Unresectable Malignant Neoplasm | Phase 1 / Phase 2 | Unknown | University Medical Center Groningen | 47 | 2019-02-14 | 2024-05-03 |
| Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer Durvalumab, IMRT 50 Gy + FOLFOX4 simplifIed (oxaliplatin, leucovorin, 5-FU) - Esophagus Cancer, Unresectable Malignant Neoplasm | Phase 2 | Completed | UNICANCER | 112 | 2018-12-05 | 2025-11-18 |
| QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. Aldoxorubicin Hydrochloride, ALT-803, ETBX-051 - Chordoma, Unresectable Malignant Neoplasm | Phase 1 / Phase 2 | Withdrawn | ImmunityBio, Inc. | 2018-08-31 | 2025-02-21 | |
| A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors Axatilimab, Durvalumab - Solid Tumor, Metastatic Tumor | Phase 1 | Completed | Syndax Pharmaceuticals | 45 | 2017-09-01 | 2024-05-17 |
| Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer 18F-FHBG, Aldesleukin, Busulfan - HLA-A*0201 Positive Cells Present, Locally Advanced Malignant Neoplasm | Phase 1 | Terminated | Jonsson Comprehensive Cancer Center | 5 | 2017-07-26 | 2023-11-01 |
| Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors Atezolizumab, Cobimetinib - Skin Squamous Cell Carcinoma, Appendix Adenocarcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 49 | 2017-04-07 | 2025-05-28 |
| Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Muscadine Grape Skin Extract, Quality-of-Life Assessment - Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm | Phase 1 | Completed | Wake Forest University Health Sciences | 24 | 2016-03-01 | 2023-06-05 |
| Genomic Sequencing in Determining Treatment in Patients With Metastatic Cancer or Cancer That Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Quality-of-Life Assessment, Targeted Therapy - Metastatic Neoplasm, Recurrent Neoplasm | Not applicable | Terminated | Wake Forest University Health Sciences | 110 | 2015-10-01 | 2018-07-02 |
| Ilorasertib in Treating Patients With CDKN2A-deficient Advanced or Metastatic Solid Cancers That Cannot Be Removed by Surgery Ilorasertib, Laboratory Biomarker Analysis - Metastatic Malignant Neoplasm, Solid Neoplasm | Phase 1 | Completed | University of Chicago | 12 | 2015-09-08 | 2019-04-22 |
| Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma Pembrolizumab - Unresectable Malignant Neoplasm, Melanoma | Phase 2 | Completed | St. Louis University | 10 | 2015-01-01 | 2019-06-20 |
| Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain Sodium Bicarbonate - Tumor, Cancer | Phase 1 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 9 | 2013-09-01 | 2015-06-04 |
| Bevacizumab in Combination With Chemotherapy in Patients With Advanced or Recurrent Non-squamous NSCLC Non-small Cell Lung Cancer, Unresectable Malignant Neoplasm | Completed | University of Athens | 150 | 2012-01-01 | 2014-12-08 | |
| Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Carboplatin, Laboratory Biomarker Analysis, Paclitaxel - Breast Carcinoma, Carcinoma of Unknown Primary | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 94 | 2011-06-20 | 2026-11-12 |
Neoplasm Metastasis (8) · Esophageal Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (2) · Melanoma (2) · Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma, Mucinous (1) · Breast Neoplasms (1) · Cancer Pain (1) · Carcinoma, Squamous Cell (1) · Carcinoma, Transitional Cell (1) · Chordoma (1) · Endometrial Neoplasms (1) · Head and Neck Neoplasms (1) · Hematologic Neoplasms (1)
Neoplasms (14) · Neoplasms by Site (9) · Neoplasms by Histologic Type (8) · Neoplastic Processes (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Esophageal Diseases (4) · Gastrointestinal Diseases (4) · Gastrointestinal Neoplasms (4) · Lung Diseases (4) · Neoplasms, Glandular and Epithelial (4) · Respiratory Tract Diseases (4) · Respiratory Tract Neoplasms (4)
Radiotherapy (2) · durvalumab (2) · 130-nm albumin-bound paclitaxel (1) · 9-(4-fluoro-3-hydroxymethylbutyl)guanine (1) · ALT-803 (1) · Albumin-Bound Paclitaxel (1) · Busulfan (1) · Carboplatin (1) · Cell- and Tissue-Based Therapy (1) · Cetuximab (1) · Cisplatin (1) · Cyclophosphamide (1) · Data Collection (1) · Drug Therapy (1) · Filgrastim (1)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (2) · Wake Forest University Health Sciences (2) · Azienda Ospedaliera di Padova (1) · Groupe Francais De Pneumo-Cancerologie (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · ImmunityBio, Inc. (1) · Jonsson Comprehensive Cancer Center (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Peking University First Hospital (1) · St. Louis University (1) · Syndax Pharmaceuticals (1) · UNICANCER (1) · University Medical Center Groningen (1) · University of Athens (1)
United States (10) · China (2) · France (2) · Greece (1) · Italy (1) · Netherlands (1)
Amit Mahipal, M.D. (1) · Angela Alistar (1) · Anouchka Modesto, Doctor (1) · E. G.E. de Vries, MD, PhD (1) · Heidi Klepin (1) · Hussein A Tawbi (1) · John M Richart, MD (1) · Kanwal P Raghav (1) · Kate Madigan, MD (1) · Kostas N Syrigos, Professor (1) · Laurent Quero, Doctor (1) · Manish Sharma (1) · Theodore Scott Nowicki, M.D. (1) · Umberto Cillo, MD (1)
PMID 29780250, PMID 33867481, PMID 36271158, PMID 36452492, PMID 36471036, PMID 39673459, PMID 39704205, PMID 40593578
P30CA012197 (2), 2018 (1), N01CM00100 (1), P30CA014599 (1), P30CA047904 (1), U01CA062490 (1), U01CA062502 (1), U01CA062505 (1), U01CA069856 (1), U01CA070095 (1), U01CA099168 (1), UM1CA186690 (1), UM1CA186691 (1), UM1CA186709 (1), UM1CA186716 (1)